BiotechTube
Home/Seres Therapeutics/Lisa von Moltke
LV

Lisa von Moltke

Chief Medical Officer

Seres Therapeutics

Therapeutic Areas

Infectious DiseaseGastroenterologyImmunology

Seres Therapeutics Pipeline

DrugIndicationPhase
VOWST™ (SER-109)Prevention of recurrent Clostridioides difficile infection (rCDI)Approved
SER-155Prevention of antibiotic-resistant infections and graft-versus-host disease (GvHD) in immunocompromised patientsPhase 1b
SER-301Ulcerative ColitisPhase 1b
SER-287Ulcerative ColitisPhase 2b

Leadership Team at Seres Therapeutics

ED
Eric D. Shaff
President and Chief Executive Officer
MR
Matthew R. Henn
Chief Scientific Officer
TJ
Thomas J. DesRosier
Chief Legal Officer and Corporate Secretary
View full Seres Therapeutics profile